<DOC>
	<DOCNO>NCT01864278</DOCNO>
	<brief_summary>The registry enroll patient claudication ischemic rest pain angiographically significant lesion superficial femoral popliteal artery . Subjects treat LUTONIX Drug Coated PTA Dilatation Catheter carry CE Mark per current Instructions Use ( IFU ) follow clinically minimum 2 year .</brief_summary>
	<brief_title>Lutonix Global SFA Registry</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Male nonpregnant female ≥18 year age ; Rutherford Clinical Category ≤ 4 ; Patient willing provide 5year informed consent comply require follow ; Stenotic obstructive vascular lesion femoropopliteal artery ; Lesion ( ) treat available LUTONIX Drug Coated PTA Dilatation Catheter device size matrix per current IFU ; At least one patent native outflow artery ankle free significant lesion ( ≥50 % stenosis ) confirm angiography ( treatment outflow disease NOT permit ; treatment inflow disease permit prior treatment LUTONIX Drug Coated PTA Dilatation Catheter ) . Patient currently participate investigational drug device study ; Inability take recommended medication state IFU noncontrollable allergy contrast ; Pregnant plan become pregnant men intend father child ; Rutherford Class &gt; 4 Known inadequate distal outflow plan future treatment vascular disease distal target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>